Identification of Nine Genomic Regions of Amplification in Urothelial Carcinoma, Correlation with Stage, and Potential Prognostic and Therapeutic Value

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Chekaluk, Yvonne ^a   Wu, Chin Lee ^b   Rosenberg, Jonathan ^c   Riester, Markus ^d   Dai, Qishan ^b   Lin, Sharron ^b   Guo, Yanan ^a   McDougal, W Scott ^b   Kwiatkowski, David J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CCND1 GENE; CLINICAL FEATURE; COHORT ANALYSIS; COPY NUMBER VARIATION; ERBB2 GENE; GENE; GENE AMPLIFICATION; GENE FUNCTION; GENE LOCATION; GENE MUTATION; GENE TARGETING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; HUMAN; HUMAN TISSUE; MDM2 GENE; MULTIPLEX INVERSION PROBE ANALYSIS; MULTIPLEX LIGATION DEPENDENT PROBE ASSAY; NUCLEOTIDE SEQUENCE; TRANSITIONAL CELL CARCINOMA; VALIDATION PROCESS;

CARCINOMA; CELL LINE, TUMOR; CHROMOSOME MAPPING; DNA COPY NUMBER VARIATIONS; GENE AMPLIFICATION; HUMANS; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; REPRODUCIBILITY OF RESULTS; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 84875960641     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060927     Document Type: Article

References (48)

1. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. National Comprehensive Cancer Network I (2012) NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer.
3. Goebell PJ, Knowles MA, (2010) Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol Oncol 28: 409-428.
4. Parada LF, Tabin CJ, Shih C, Weinberg RA, (1982) Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 297: 474-478.
5. Sidransky D, Von Eschenbach A, Tsai YC, Jones P, Summerhayes I, et al. (1991) Identification of p53 gene mutations in bladder cancers and urine samples. Science 252: 706-709.
6. Williamson MP, Elder PA, Shaw ME, Devlin J, Knowles MA, (1995) p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet 4: 1569-1577.
7. Hornigold N, Devlin J, Davies AM, Aveyard JS, Habuchi T, et al. (1999) Mutation of the 9q34 gene TSC1 in sporadic bladder cancer. Oncogene 18: 2657-2661.
8. Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, et al. (1999) Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 23: 18-20.
9. Kallioniemi A, Kallioniemi OP, Citro G, Sauter G, DeVries S, et al. (1995) Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization. Genes Chromosomes Cancer 12: 213-219.
10. Voorter C, Joos S, Bringuier PP, Vallinga M, Poddighe P, et al. (1995) Detection of chromosomal imbalances in transitional cell carcinoma of the bladder by comparative genomic hybridization. Am J Pathol 146: 1341-1354.
11. Richter J, Jiang F, Gorog JP, Sartorius G, Egenter C, et al. (1997) Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res 57: 2860-2864.
12. Simon R, Burger H, Brinkschmidt C, Bocker W, Hertle L, et al. (1998) Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. J Pathol 185: 345-351.
13. Blaveri E, Brewer JL, Roydasgupta R, Fridlyand J, DeVries S, et al. (2005) Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res 11: 7012-7022.
14. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, et al. (2010) AJCC Cancer Staging Manual: Springer.
15. Platt FM, Hurst CD, Taylor CF, Gregory WM, Harnden P, et al. (2009) Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res 15: 6008-6017.
16. Wang Y, Carlton VE, Karlin-Neumann G, Sapolsky R, Zhang L, et al. (2009) High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays. BMC Med Genomics 2: 8.
17. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, et al. (2006) GenePattern 2.0. Nat Genet 38: 500-501.
18. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, et al. (2007) Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A 104: 20007-20012.
19. Kozlowski P, Roberts P, Dabora S, Franz D, Bissler J, et al. (2007) Identification of 54 large deletions/duplications in TSC1 and TSC2 using MLPA, and genotype-phenotype correlations. Hum Genet 121: 389-400.
20. van Rhijn BW, van der Kwast TH, Vis AN, Kirkels WJ, Boeve ER, et al. (2004) FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 64: 1911-1914.
21. Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S, et al. (2003) FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 63: 8108-8112.
22. Forbes SA, Tang G, Bindal N, Bamford S, Dawson E, et al. (2010) COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res 38: D652-657.
23. Lee HW, Seol HJ, Choi YL, Ju HJ, Joo KM, et al. (2012) Genomic copy number alterations associated with the early brain metastasis of non-small cell lung cancer. Int J Oncol 41: 2013-20.
24. Hasselblatt M, Isken S, Linge A, Eikmeier K, Jeibmann A, et al. (2013) High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors. Genes Chrom Cancer 52: 185-90.
25. Jahromi MS, Putnam AR, Druzgal C, Wright J, Spraker-Perlman H, et al. (2012) Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma. Cancer Genet 205: 391-404.
26. Johnson CE, Gorringe KL, Thompson ER, Opeskin K, Boyle SE, et al. (2012) Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma. Breast Cancer Res Treat 133: 889-98.
27. Thompson PA, Brewster AM, Kim-Anh D, Baladandayuthapani V, Broom BM, et al. (2011) Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer. PLoS One 6: e23543.
28. Cheng L, Zhang S, MacLennan GT, Williamson SR, Lopez-Beltran A, et al. (2011) Bladder cancer: translating molecular genetic insights into clinical practice. Hum Pathol 42: 455-481.
29. Feber A, Clark J, Goodwin G, Dodson AR, Smith PH, et al. (2004) Amplification and overexpression of E2F3 in human bladder cancer. Oncogene 23: 1627-1630.
30. Fleischmann A, Rotzer D, Seiler R, Studer UE, Thalmann GN, (2011) Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol 60: 350-357.
31. Hurst CD, Tomlinson DC, Williams SV, Platt FM, Knowles MA, (2008) Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification. Oncogene 27: 2716-2727.
32. Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, et al. (2010) FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 5: e13821.
33. Lae M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P, et al. (2010) Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol 21: 815-819.
34. Lopez-Beltran A, Ordonez JL, Otero AP, Blanca A, Sevillano V, et al. (2010) Cyclin D3 gene amplification in bladder carcinoma in situ. Virchows Arch 457: 555-561.
35. Mhawech-Fauceglia P, Cheney RT, Schwaller J, (2006) Genetic alterations in urothelial bladder carcinoma: an updated review. Cancer 106: 1205-1216.
36. Nord H, Segersten U, Sandgren J, Wester K, Busch C, et al. (2010) Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma. Int J Cancer 126: 1390-1402.
37. Prat E, del Rey J, Ponsa I, Nadal M, Camps J, et al. (2010) Comparative genomic hybridization analysis reveals new different subgroups in early-stage bladder tumors. Urology 75: 347-355.
38. Richter J, Beffa L, Wagner U, Schraml P, Gasser TC, et al. (1998) Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization. Am J Pathol 153: 1615-1621.
39. Veerakumarasivam A, Scott HE, Chin SF, Warren A, Wallard MJ, et al. (2008) High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53. Clin Cancer Res 14: 2527-2534.
40. Obermann EC, Junker K, Stoehr R, Dietmaier W, Zaak D, et al. (2003) Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses. J Pathol 199: 50-57.
41. Knowles MA (2008) Bladder cancer subtypes defined by genomic alterations. Scand J Urol Nephrol Suppl: 116-130.
42. Sjodahl G, Lauss M, Gudjonsson S, Liedberg F, Hallden C, et al. (2011) A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. PLoS One 6: e18583.
43. Gui Y, Guo G, Huang Y, Hu X, Tang A, et al. (2011) Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 43: 875-878.
44. Mao JH, Kim IJ, Wu D, Climent J, Kang HC, et al. (2008) FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 321: 1499-1502.
45. Hindson BJ, Ness KD, Masquelier DA, Belgrader P, Heredia NJ, et al. (2011) High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem 83: 8604-8610.
46. Kim JK, Diehl JA, (2009) Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol 220: 292-296.
47. Baselga J, Swain SM, (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9: 463-475.
48. Yuan Y, Liao YM, Hsueh CT, Mirshahidi HR, (2011) Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. J Hematol Oncol 4: 16.